PrimaPharma Revenue and Competitors
Estimated Revenue & Valuation
- PrimaPharma's estimated annual revenue is currently $20.9M per year.
- PrimaPharma's estimated revenue per employee is $201,000
Employee Data
- PrimaPharma has 104 Employees.
- PrimaPharma grew their employee count by 16% last year.
PrimaPharma's People
Name | Title | Email/Phone |
---|---|---|
1 | Manufacturing Lead | Reveal Email/Phone |
2 | Manufacturing Associate II | Reveal Email/Phone |
3 | Quality Assurance Associate II | Reveal Email/Phone |
PrimaPharma Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $84.8M | 422 | 24% | N/A | N/A |
#2 | $0.4M | 2 | 0% | N/A | N/A |
#3 | $32M | 159 | 3% | N/A | N/A |
#4 | $35M | 121 | 3% | $62.5M | N/A |
#5 | $30.2M | 150 | 18% | N/A | N/A |
#6 | $135.3M | 673 | 0% | N/A | N/A |
#7 | $110.3M | 549 | N/A | N/A | N/A |
#8 | $60.1M | 299 | -4% | N/A | N/A |
#9 | $554.8M | 1725 | 2% | N/A | N/A |
#10 | $10.5M | 52 | 4% | N/A | N/A |
What Is PrimaPharma?
PrimaPharma is a Contract Development and Manufacturing Organization ("CDMO") manufacturing prescription and over-the-counter drugs, medical devices, and clinical trial materials. Established in 1992, the Company is ISO 13485 certified, and its facility is routinely inspected by the FDA. PrimaPharma's core competencies include aseptic fill and finish of injectables and ophthalmics. In 2016, PrimaPharma will be adding Blow Fill Seal production technology and automated syringe and vial filling to its service offerings.
keywords:N/AN/A
Total Funding
104
Number of Employees
$20.9M
Revenue (est)
16%
Employee Growth %
N/A
Valuation
N/A
Accelerator
PrimaPharma News
... The Ritedose Corporation, Unicep Packaging, Laboratorios SALVAT, S.A, PrimaPharma , Asept Pak, Plastikon, Birgi Mefar Group, Pharmapack,...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $14.6M | 104 | 2% | N/A |
#2 | $30.8M | 104 | -35% | $1.2B |
#3 | $26.7M | 104 | 6% | N/A |
#4 | $27.6M | 104 | 5% | N/A |
#5 | $30.2M | 104 | -8% | N/A |